tiprankstipranks
Advertisement
Advertisement
ANI Pharmaceuticals backs FY26 adjusted EPS view $9.19-$9.69, consensus $9.42
PremiumThe FlyANI Pharmaceuticals backs FY26 adjusted EPS view $9.19-$9.69, consensus $9.42
7d ago
ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9d ago
ANI Pharmaceuticals initiated with a Hold at Canaccord
Premium
The Fly
ANI Pharmaceuticals initiated with a Hold at Canaccord
28d ago
ANI Pharmaceuticals Signals Confident 2026 Growth Path
PremiumCompany AnnouncementsANI Pharmaceuticals Signals Confident 2026 Growth Path
2M ago
ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
Premium
Company Announcements
ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan
3M ago
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
Premium
Company Announcements
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
3M ago
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
PremiumThe FlyANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
4M ago
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
Premium
The Fly
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
4M ago
ANI Pharmaceuticals announces publication of iluvien clinical trial results
Premium
The Fly
ANI Pharmaceuticals announces publication of iluvien clinical trial results
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100